Why do astrocytic plaques remain specific to CBD despite shared tau pathways with other tauopathies?

OPEN

The abstract notes astrocytic plaques are a CBD hallmark that rarely occurs in aging or other neurodegenerative diseases, despite CBD sharing similar cell vulnerability and transmission pathways with multiple proteinopathies. This selectivity mechanism is unexplained and could reveal disease-specific therapeutic targets. Gap type: unexplained_observation Source paper: Age-Related Pathology in Corticobasal Degeneration. (2024, International journal of molecular sciences, PMID:38473986)

Priority: 0.80 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Why do astrocytic plaques remain specific to CBD despite shared tau pathways with other tauopathies? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Why do astrocytic plaques remain specific to CBD despite shared tau pathways with other tauopathies? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (3)

CBDTRPV4CBDmitochondrial dysfunctionCBDPINK1

aggregates in (1)

tau_proteinCBD

biomarker for (1)

4R-tauCBD

causes (1)

4r-tauCBD

co discussed (39)

BASAL GANGLIACBDBRAINSTEMCBDCBDTAUALZHEIMERCBDALZHEIMER'SCBD
▸ Show 34 more

inhibits (1)

CBDamyloid-β

interacts with (1)

CBDtemozolomide

regulates (1)

CBDtau protein

treats (2)

CBDgliomaCBDAlzheimer's disease
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps